Eli Lilly (LLY) Rises But Trails Market: What Investors Should KnowZacks Investment Research • 03/31/25
Eli Lilly Reverses Its Recent Upswing On Broader Market Woes. Is It A Sell?Investors Business Daily • 03/31/25
Lilly's lepodisiran reduced levels of genetically inherited heart disease risk factor, lipoprotein(a), by nearly 94% from baseline at the highest tested dose in adults with elevated levelsPRNewsWire • 03/30/25
CHMP Recommends Against Approval of Eli Lilly's Kisunla Alzheimer's Drug -- UpdateMarket Watch • 03/28/25
Billionaires Stanley Druckenmiller, Chase Coleman, and Stephen Mandel Jr. Are Piling Into This Growth Stock That's Beating the S&P 500The Motley Fool • 03/28/25
How Tariffs Are Rocking The 'Bubblegum And Shoestring' Medical Supply ChainInvestors Business Daily • 03/27/25
Beyond GLP-1 Drugs: This Opportunity at Eli Lilly Could Surprise Everyone in 2025The Motley Fool • 03/27/25
Eli Lilly, Palo Alto Networks Traders Take Note: Direxion's New Leveraged ETFs Are HereBenzinga • 03/26/25
Lilly announces details of presentations at 2025 American Association for Cancer Research (AACR) Annual MeetingPRNewsWire • 03/25/25